GlassScriptPhysician profile
Tayler Williams
NPI 1942820634
$2,461.30
in general payments reported to CMS, 2019-2025
24 companies · $676 in 2025
The $676 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.99 · 2023: $404 · 2024: $1,356 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.74 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $398.79 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $262.04 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $218.84 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $149.96 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $108.51 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.68 | 2023-2025 | Trintellix |
| Amgen INC. | $85.61 | 2024-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $70.09 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $66.00 | 2023-2024 | Rexulti |
| Philips North America LLC | $63.07 | 2024 | (Ck6) Holter |
| Boston Scientific Corporation | $55.62 | 2024-2025 | Watchman Access System |
| Astellas Pharma US INC | $39.12 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $35.78 | 2023-2024 | Arexvy, Shingrix |
| Medtronic, INC. | $30.08 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $28.75 | 2025 | Ibsrela |
| Organon LLC | $24.99 | 2022 | |
| Dexcom, INC. | $24.81 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.49 | 2025 | Jardiance |
| Dynavax Technologies Corporation | $21.56 | 2024 | Heplisav-B |
| Vanda Pharmaceuticals INC. | $21.54 | 2024 | Fanapt |
| Abbott Laboratories | $18.18 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $16.40 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.65 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayler Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.